Traditionally, using enzymes for chemical synthesis requires keeping them inside living microbes via fermentation, which forces systems to balance cellular survival with product generation. HydRegen, a spinout from the University of Oxford, is working to bypass these biological limitations by utilizing isolated enzymes outside of living cells. The company is specifically commercializing methods that deploy immobilized hydrogenase enzymes directly within conventional chemical reactors.
The latest financial backing highlights growing investor interest in cell-free biosynthesis, an approach designed to give chemical manufacturers greater control and efficiency by removing the constraints of intact microbial metabolism.